Cargando…

Changes in Gut Microbiota Correlates with Response to Treatment with Probiotics in Patients with Atopic Dermatitis. A Post Hoc Analysis of a Clinical Trial

Atopic dermatitis (AD) is a chronic recurrent inflammatory skin disease with a high impact on the comfort of those who are affected and long-term treated with corticosteroids with limited efficacy and a high prevalence of relapses. Because of the limited effectiveness of these treatments, new strate...

Descripción completa

Detalles Bibliográficos
Autores principales: Climent, Eric, Martinez-Blanch, Juan Francisco, Llobregat, Laura, Ruzafa-Costas, Beatriz, Carrión-Gutiérrez, Miguel Ángel, Ramírez-Boscá, Ana, Prieto-Merino, David, Genovés, Salvador, Codoñer, Francisco M., Ramón, Daniel, Chenoll, Empar, Navarro-López, Vicente
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8071520/
https://www.ncbi.nlm.nih.gov/pubmed/33921166
http://dx.doi.org/10.3390/microorganisms9040854
_version_ 1783683727452274688
author Climent, Eric
Martinez-Blanch, Juan Francisco
Llobregat, Laura
Ruzafa-Costas, Beatriz
Carrión-Gutiérrez, Miguel Ángel
Ramírez-Boscá, Ana
Prieto-Merino, David
Genovés, Salvador
Codoñer, Francisco M.
Ramón, Daniel
Chenoll, Empar
Navarro-López, Vicente
author_facet Climent, Eric
Martinez-Blanch, Juan Francisco
Llobregat, Laura
Ruzafa-Costas, Beatriz
Carrión-Gutiérrez, Miguel Ángel
Ramírez-Boscá, Ana
Prieto-Merino, David
Genovés, Salvador
Codoñer, Francisco M.
Ramón, Daniel
Chenoll, Empar
Navarro-López, Vicente
author_sort Climent, Eric
collection PubMed
description Atopic dermatitis (AD) is a chronic recurrent inflammatory skin disease with a high impact on the comfort of those who are affected and long-term treated with corticosteroids with limited efficacy and a high prevalence of relapses. Because of the limited effectiveness of these treatments, new strategies for recovery from AD lesions are continually being explored. In this article, we describe the gut microbiome changes achieved in a recently published clinical trial with the probiotic formulation Bifidobacterium animalis subsp. lactis CECT 8145, Bifidobacterium longum CECT 7347, and Lacticaseibacillus casei CECT 9104 (formerly Lactobacillus casei CECT 9104), showing a significant improvement in SCORAD (scoring atopic dermatitis) index in children (4–17 years) with AD (Clinicaltrials.gov identifier: NCT02585986). The present gut microbiome post hoc study showed no significant changes in diversity (Shannon and Simpson indexes) after probiotic consumption. In the probiotic group, genera Bacteroides, Ruminococcus, and Bifidobacterium significantly increased their levels while Faecalibacterium decreased, compared to the placebo group. Faecalibacterium showed the highest presence and significant positive correlation with AD severity (SCORAD index), whereas Abyssivirga, Bifidobacterium, and Lactococcus were inversely correlated. The results suggest that the consumption of the probiotic formulation here assayed modulates the gut microbiome with significant changes in genera Bacteroides and Faecalibacterium. In turn, the improvement in SCORAD correlates with a decrease in Faecalibacterium and an increase in Bifidobacterium, among others.
format Online
Article
Text
id pubmed-8071520
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-80715202021-04-26 Changes in Gut Microbiota Correlates with Response to Treatment with Probiotics in Patients with Atopic Dermatitis. A Post Hoc Analysis of a Clinical Trial Climent, Eric Martinez-Blanch, Juan Francisco Llobregat, Laura Ruzafa-Costas, Beatriz Carrión-Gutiérrez, Miguel Ángel Ramírez-Boscá, Ana Prieto-Merino, David Genovés, Salvador Codoñer, Francisco M. Ramón, Daniel Chenoll, Empar Navarro-López, Vicente Microorganisms Article Atopic dermatitis (AD) is a chronic recurrent inflammatory skin disease with a high impact on the comfort of those who are affected and long-term treated with corticosteroids with limited efficacy and a high prevalence of relapses. Because of the limited effectiveness of these treatments, new strategies for recovery from AD lesions are continually being explored. In this article, we describe the gut microbiome changes achieved in a recently published clinical trial with the probiotic formulation Bifidobacterium animalis subsp. lactis CECT 8145, Bifidobacterium longum CECT 7347, and Lacticaseibacillus casei CECT 9104 (formerly Lactobacillus casei CECT 9104), showing a significant improvement in SCORAD (scoring atopic dermatitis) index in children (4–17 years) with AD (Clinicaltrials.gov identifier: NCT02585986). The present gut microbiome post hoc study showed no significant changes in diversity (Shannon and Simpson indexes) after probiotic consumption. In the probiotic group, genera Bacteroides, Ruminococcus, and Bifidobacterium significantly increased their levels while Faecalibacterium decreased, compared to the placebo group. Faecalibacterium showed the highest presence and significant positive correlation with AD severity (SCORAD index), whereas Abyssivirga, Bifidobacterium, and Lactococcus were inversely correlated. The results suggest that the consumption of the probiotic formulation here assayed modulates the gut microbiome with significant changes in genera Bacteroides and Faecalibacterium. In turn, the improvement in SCORAD correlates with a decrease in Faecalibacterium and an increase in Bifidobacterium, among others. MDPI 2021-04-15 /pmc/articles/PMC8071520/ /pubmed/33921166 http://dx.doi.org/10.3390/microorganisms9040854 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Climent, Eric
Martinez-Blanch, Juan Francisco
Llobregat, Laura
Ruzafa-Costas, Beatriz
Carrión-Gutiérrez, Miguel Ángel
Ramírez-Boscá, Ana
Prieto-Merino, David
Genovés, Salvador
Codoñer, Francisco M.
Ramón, Daniel
Chenoll, Empar
Navarro-López, Vicente
Changes in Gut Microbiota Correlates with Response to Treatment with Probiotics in Patients with Atopic Dermatitis. A Post Hoc Analysis of a Clinical Trial
title Changes in Gut Microbiota Correlates with Response to Treatment with Probiotics in Patients with Atopic Dermatitis. A Post Hoc Analysis of a Clinical Trial
title_full Changes in Gut Microbiota Correlates with Response to Treatment with Probiotics in Patients with Atopic Dermatitis. A Post Hoc Analysis of a Clinical Trial
title_fullStr Changes in Gut Microbiota Correlates with Response to Treatment with Probiotics in Patients with Atopic Dermatitis. A Post Hoc Analysis of a Clinical Trial
title_full_unstemmed Changes in Gut Microbiota Correlates with Response to Treatment with Probiotics in Patients with Atopic Dermatitis. A Post Hoc Analysis of a Clinical Trial
title_short Changes in Gut Microbiota Correlates with Response to Treatment with Probiotics in Patients with Atopic Dermatitis. A Post Hoc Analysis of a Clinical Trial
title_sort changes in gut microbiota correlates with response to treatment with probiotics in patients with atopic dermatitis. a post hoc analysis of a clinical trial
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8071520/
https://www.ncbi.nlm.nih.gov/pubmed/33921166
http://dx.doi.org/10.3390/microorganisms9040854
work_keys_str_mv AT climenteric changesingutmicrobiotacorrelateswithresponsetotreatmentwithprobioticsinpatientswithatopicdermatitisaposthocanalysisofaclinicaltrial
AT martinezblanchjuanfrancisco changesingutmicrobiotacorrelateswithresponsetotreatmentwithprobioticsinpatientswithatopicdermatitisaposthocanalysisofaclinicaltrial
AT llobregatlaura changesingutmicrobiotacorrelateswithresponsetotreatmentwithprobioticsinpatientswithatopicdermatitisaposthocanalysisofaclinicaltrial
AT ruzafacostasbeatriz changesingutmicrobiotacorrelateswithresponsetotreatmentwithprobioticsinpatientswithatopicdermatitisaposthocanalysisofaclinicaltrial
AT carriongutierrezmiguelangel changesingutmicrobiotacorrelateswithresponsetotreatmentwithprobioticsinpatientswithatopicdermatitisaposthocanalysisofaclinicaltrial
AT ramirezboscaana changesingutmicrobiotacorrelateswithresponsetotreatmentwithprobioticsinpatientswithatopicdermatitisaposthocanalysisofaclinicaltrial
AT prietomerinodavid changesingutmicrobiotacorrelateswithresponsetotreatmentwithprobioticsinpatientswithatopicdermatitisaposthocanalysisofaclinicaltrial
AT genovessalvador changesingutmicrobiotacorrelateswithresponsetotreatmentwithprobioticsinpatientswithatopicdermatitisaposthocanalysisofaclinicaltrial
AT codonerfranciscom changesingutmicrobiotacorrelateswithresponsetotreatmentwithprobioticsinpatientswithatopicdermatitisaposthocanalysisofaclinicaltrial
AT ramondaniel changesingutmicrobiotacorrelateswithresponsetotreatmentwithprobioticsinpatientswithatopicdermatitisaposthocanalysisofaclinicaltrial
AT chenollempar changesingutmicrobiotacorrelateswithresponsetotreatmentwithprobioticsinpatientswithatopicdermatitisaposthocanalysisofaclinicaltrial
AT navarrolopezvicente changesingutmicrobiotacorrelateswithresponsetotreatmentwithprobioticsinpatientswithatopicdermatitisaposthocanalysisofaclinicaltrial